Skip to main content
Clinical Trials/NCT05286138
NCT05286138
Recruiting
Not Applicable

STUDY MULTICENRIC OBSERVATIONAL, NO-PROFIT FOR THE INCIDENCE AND CHARACTERISTICS OF MALIGNANT NEOPLASIES IN PATIENTS WITH HEMOGLOBINOPATHY FOLLOWED IN ITALY

Società Italiana Talassemie ed Emoglobinopatie1 site in 1 country10,000 target enrollmentStarted: February 1, 2022Last updated:

Overview

Phase
Not Applicable
Status
Recruiting
Sponsor
Società Italiana Talassemie ed Emoglobinopatie
Enrollment
10,000
Locations
1
Primary Endpoint
outcome 1

Overview

Brief Summary

The Trial aims to increase the information available on the relevance of tumor pathology in hemoglobinopathies, updating the data relating to hepatocarcinoma and investigating which other tumors are more frequent in patients with hemoglobinopathies. Still, in relation to tumor pathology, the study will evaluate any differences between the different types of hemoglobinopathy and will investigate the association between the appearance of neoplasms and risk factors such as age, sex, iron accumulation markers, history of bone marrow transplant, and others.

Detailed Description

By providing targeted screening strategies, these data may contribute to the early identification of tumor pathology in hemoglobinopathies, and, by contributing to the identification of risk factors, to its prevention. They will also be able to contribute to understanding which therapeutic approaches in the case of cancer are most appropriate in this category of subjects.

To be able to go even deeper into understanding the possible link that exists between tumors and hemoglobinopathy, a further data collection (substudy) has been prepared in which additional and more detailed information will be collected in order to evaluate which is the percentage of patients who develop tumors compared to all those with hemoglobinopathy.

The risk of developing tumors will also be assessed for each hemoglobinopathy (transfusion-dependent beta-thalassemia, transfusion independent beta-thalassemia, hemoglobin H disease, sickle cell disease, microdrepanocytosis)

Study Design

Study Type
Observational
Observational Model
Other
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to 100 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Transfusion-dependent or independent beta-thalassemia, hemoglobin H disease, sickle cell anemia and microdrepanocytosis
  • Current or previous malignant tumor pathology
  • Availability of medical history including the most relevant clinical and instrumental data before the onset of cancer

Exclusion Criteria

  • - Other haematological diseases other than hemoglobinopathies
  • Absence of neoplastic events in the clinical history
  • Non-availability of relevant clinical and instrumental data

Outcomes

Primary Outcomes

outcome 1

Time Frame: ENROLLMENT STUDY

Evaluate the number of patients with hemoglobinopathy followed at Italian centers that have developed neoplastic events in the last decades

outcome 2

Time Frame: enrollment study

Evaluate which neoplasms are most associated with hemoglobinopathies

outcome 3

Time Frame: enrollment study

Identify any risk factors for the onset of neoplasms in patients with hemoglobinopathies.

Secondary Outcomes

  • outcome 4(enrollment study)
  • outcome 5(enrollment study)
  • outcome 6(enrollment study)
  • outcome 7(enrollment study)
  • outcome 8(enrollment study)

Investigators

Sponsor
Società Italiana Talassemie ed Emoglobinopatie
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials